

# Product Pipeline

	Phase I	Phase II	Phase III	Registration	Approval
<b><u>Neratinib: Tyrosine kinase inhibitor</u></b>					
<b>HER2+ Breast Cancer</b>					
<b>Extended adjuvant</b> <i>Neratinib monotherapy</i>			ExteNET (Phase III HER2+ EBC*)		
		CONTROL			
<b>Metastatic</b> <i>Monotherapy or combo therapy</i>			NALA (Phase III 3 <sup>rd</sup> Line HER2+ MBC**)		
<b>Metastatic w/ brain mets</b> <i>Monotherapy or combo therapy</i>		TBCRC-022 (T-DM1 + neratinib)			
<b><u>Alisertib: Aurora kinase A inhibitor</u></b>					
<b>HRc+*** HER2-negative MBC</b>		TBCRC-041 (fulvestrant + alisertib)			
		ALISCA-Breast1 (alisertib+endocrine)	<b>Initiation in Q4 '24</b>		
<b>Metastatic EGFR-mutant NSCLC****</b>		NCT04085315 (alisertib+osimertinib)			
<b>Small cell lung cancer</b>		NCT02038647 (paclitaxel + alisertib)			
		ALISCA-Lung1 (PUMA-ALI-4201)	<b>Initiated in Q1'24</b>		

\*